MIM
LCTX icon

MetLife Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

MetLife Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-78,181
Closed -$78K – 2868
2024
Q2 		$78K Buy
78,181
+8,472
+12% +$9.36K ﹤0.01% 2688
2024
Q1 		$103K Buy
69,709
+955
+1% +$1.08K ﹤0.01% 2521
2023
Q4 		$74.9K Hold
68,754
– – ﹤0.01% 2720
2023
Q3 		$81.1K Hold
68,754
– – ﹤0.01% 2685
2023
Q2 		$96.9K Buy
+68,754
New +$95K ﹤0.01% 2699
2022
Q1 		– Sell
-49,379
Closed -$121K – 2753
2021
Q4 		$121K Buy
49,379
+32,752
+197% +$76.7K ﹤0.01% 2335
2021
Q3 		$41.9K Sell
16,627
-33,932
-67% -$87.1K ﹤0.01% 2538
2021
Q2 		$144K Buy
+50,559
New +$131K ﹤0.01% 2339

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MetLife Investment Management's LCTX Position: Q3 2024 in Review

MetLife Investment Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2024, closing a stake of 78,181 shares — an estimated $78K sold.

MetLife Investment Management first reported a position in LCTX in Q2 2021 and held it in 8 quarters. The position peaked at $144K in Q2 2021. 114 funds tracked by Wall St. Rank hold LCTX as of Q3 2024.

  • MetLife Investment Management reported no remaining Lineage Cell Therapeutics position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 78,181 Lineage Cell Therapeutics shares in Q3 2024, an estimated $78K.
  • MetLife Investment Management first reported a position in Lineage Cell Therapeutics in Q2 2021 and held it in 8 quarters.
  • MetLife Investment Management's Lineage Cell Therapeutics position peaked at $144K in Q2 2021.
  • 114 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.